AzTrials
AzTrials

Seaweed Associated Changes in Healthy SubjectsNCT01663792

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

A study testing Seaweed in people with Seaweed Associated Changes in Healthy Subjects, run by University of South Carolina at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Could daily consumption of seaweed help explain lower postmenopausal breast cancer (BC) incidence and mortality rates in Japan? This small proof of principle clinical trial was designed to test the idea that the same amount of seaweed normally eaten in Japan would induce metabolic changes when given to non-seaweed… Read more about this study

Who is it for?
Ages 45 to 68 years, women onlyHealthy volunteers can take part
What is being tested?
Seaweed
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
15 participants
Where
1 siteUnited States
Study dates
Oct 2006to Dec 2007
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 68 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy
  • Postmenopausal (verified by follicle stimulating hormone (FSH) [23.0-116 mIU/ml]
  • Omnivorous eating habits (including meat and dairy products more than twice per week)
  • Limit alcoholic intake to ≤ 1 drink (12 g alcohol)/week

Who cannot join

  • No allergies to seaweed, soy, shellfish or iodine
  • No current use of tobacco
  • No hormone replacement therapy
  • For BC survivors, no chemotherapy or radiation treatments within the preceding 6 months
  • No history of cancer (other than BC or squamous cell skin cancer) within the previous 20 years
  • No current gastrointestinal disorders or diabetes
  • No oral antibiotics taken in the previous 3 months

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of South Carolina Cancer Research Center

    Columbia, South Carolina, 29208

Other trials in United States

About this study

Could daily consumption of seaweed help explain lower postmenopausal breast cancer (BC) incidence and mortality rates in Japan? This small proof of principle clinical trial was designed to test the idea that the same amount of seaweed normally eaten in Japan would induce metabolic changes when given to non-seaweed consuming healthy postmenopausal American women. The participants were given 10 capsules a day (about 1 tablespoon) for 3 months. During the first month the capsules contained placebo, the second month seaweed, and the third month placebo. We collected blood and urine samples after each treatment period and tested for changes in protein expression that might be related to consuming seaweed.

Read the detailed description

The relationship between the relative breast cancer (BC) risk and seaweed intake among humans is only now unfolding. A small body of research, both in vivo and in vitro, suggests seaweed may be useful in BC prevention (Funahashi et al. 1999; Teas et al. 1984; Yamamoto et al. 1987) . Seaweeds are specifically used to treat tumors in Traditional Chinese Medicine and Japanese folk medicine. On a population level, those people for whom seaweed is a regular part of their diet, most notably in Japan, have dramatically lower rates of BC (Hebert et al. 1998; Hebert and Rosen 1996; Kodama et al. 1991).

Epidemiologic studies done in Japan in the 1980s, before Westernized diets were common, reported that Japanese women had 1/3 the rate of premenopausal BC and 1/9 the rate of postmenopausal BC (Ferlay et al. 2001; Reddy et al. 1980). Even today, BC incidence rates for women in Japan are 20/100,000 compared to the U.S. average of 118/100,000 (Statistics 2007) . Although genetic predisposition has been proposed, when rates among migrants from Japan to the US are compared, BC incidence almost doubles after 10 years of residence in the US (20/100,000 to 35/100,000) (Shimizu et al. 1991), increase with each successive generation (LeMarchand et al. 1985). Japanese-American women who develop BC have significantly better survival rates than other American ethnic groups (Kanemori and Prygrocki 2005; Pineda et al. 2001). On the other hand, Asian-American women over 50 years of age living in Los Angeles, especially Japanese-American women, have one of the most rapidly increasing BC incidence rates (Deapen et al. 2002). These data support the hypothesis that lifestyle changes and possibly gene-nutrient interactions are important in BC susceptibility.

Seaweed is a typical part of East-Asian diets, although consumption varies widely among individuals (Fukuda et al. 2007). Seaweeds have no land equivalents in terms of their specific components of fiber (alginate), primary carotenoid (fucoxanthin), sulfated polysaccharide (fucoidan and laminarin), and polyphenol defense compounds, each of which has been reported to have strong anti-cancer activity (Kotake-Nara et al. 2005; Koyanagi et al. 2003; Miao et al. 1999; Son et al. 2003).

Many in vivo and in vitro studies of dietary seaweed report decreased angiogenesis and increased apoptosis of tumor cells (Konishi et al. 2006; Koyanagi et al. 2003; Sekiya et al. 2005), inhibition of tumor cell adhesion and metastasis (Liu et al. 2005) and enhanced immune responses (Maruyama et al. 2003; Maruyama et al. 2006). Nishino and colleagues have investigated seaweed modulation of the urokinase plasminogen system (Nishino et al. 1999; Nishino et al. 2000). Based on the wide range of antitumor effects, we investigated the possibility that seaweed could affect uPAR concentrations in women who consume seaweed. The urokinase-type plasminogen activator (uPA), urokinase-type plasminogen activator receptor (uPAR, CD87), and its plasminogen inhibitors 1 and 2 are central to the maintenance of homeostasis, directly affecting the extracellular matrix (ECM), inflammation, tissue repair. Increased concentrations have been shown to be associated with more rapid cancer progression (Foekens et al. 2000). Urinary concentration of uPAR is highly correlated with urinary uPA concentrations, and both are correlated with tissue concentration (Foekens et al. 2000; Sier et al. 2004).When uPA/uPAR concentrations are increased, there is increased ECM degradation that allows cancer cells to migrate, leading to metastases. Urokinase is also used therapeutically to treat serious conditions involving blood clots. In clinical studies, tissue concentration of uPA is an independent prognostic predictor of BC progression (Ceccarelli et al. 2010; Look et al. 2002).

We therefore included evaluation of one part of the urokinase system, uPAR, in this study as a possible biomarker for seaweed activity that might be related to BC prevention.

To further assess whether a dietary seaweed intervention could alter protein expression in urine and serum in a non-seaweed consuming population of healthy postmenopausal women, we used surface enhanced laser desorption/ionization time of flight coupled with mass spectrometer (SELDI-TOF-MS). Proteomic analyses have been used to identify cancer biomarkers with high sensitivity and specificity, including those related to BC (Gast et al. 2008; Shimizu et al. 1991; van Winden et al. 2009). SELDI has also been shown to be sensitive enough to be used to identify changes in serum associated with the addition of a novel food (green tea) (Tsuneki et al. 2004).

Being tested
Seaweed, Placebo, Placebo2
Keywords
urokinase receptor, protein expression, seaweed (Undaria pinnatifida)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SeaweedOther

    Also called Undaria pinnatifida

    Ten 500-mg capsules to be taken orally each day for 1 month

  • PlaceboOther

    Also called Maltodextrin

    Ten 500-mg capsules to be taken orally each day for 1 month

  • Placebo2Other

    Also called Maltodextrin

    Ten 500-mg capsules to be taken orally each day for 1 month

Study groups in NCT01663792
Study groupRoleWhat they receive
PlaceboPlacebo comparator5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month
Receives: Other: Placebo
SeaweedExperimentalSeaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month
Receives: Other: Seaweed
Placebo2Placebo comparator5 g/d placebo in 10 500-mg capsules for one month
Receives: Other: Placebo2

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Urinary urokinase receptor concentration

    ELISA test for uPAR concentration

    Measured: 3 months

  2. Surface Enhanced Laser Desorption/Ionization-Time Of Flight-Mass Spectrometry (SELDI-TOF-MS)identification of urinary and serum protein changes

    SELDI-TOF-MS was used to measure urinary and serum protein changes

    Measured: 3 months

Secondary outcomes (1)
  1. Urinary iodine concentrations

    Urinary iodine concentration changes were used to indicate adherence to taking the seaweed supplement.

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2012 (estimated)
  2. Study startOct 2006
  3. Primary completionDec 2007
  4. Study completionDec 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01663792
Sponsor's protocol ID
DAMD-17-98-1-8207
Status last verified
May 2021
First submitted
9 Aug 2012
Last updated
11 May 2021
Results posted
No
Data monitoring committee
No

Publications

  • Funahashi H, Imai T, Tanaka Y, Tsukamura K, Hayakawa Y, Kikumori T, Mase T, Itoh T, Nishikawa M, Hayashi H, Shibata A, Hibi Y, Takahashi M, Narita T. Wakame seaweed suppresses the proliferation of 7,12-dimethylbenz(a)-anthracene-induced mammary tumors in rats. Jpn J Cancer Res. 1999 Sep;90(9):922-7. doi: 10.1111/j.1349-7006.1999.tb00836.x.

    PubMed 10551319
  • Teas J, Harbison ML, Gelman RS. Dietary seaweed (Laminaria) and mammary carcinogenesis in rats. Cancer Res. 1984 Jul;44(7):2758-61.

    PubMed 6426785
  • Yamamoto I, Maruyama H, Moriguchi M. The effect of dietary seaweeds on 7,12-dimethyl-benz[a]anthracene-induced mammary tumorigenesis in rats. Cancer Lett. 1987 May;35(2):109-18. doi: 10.1016/0304-3835(87)90033-4.

    PubMed 3107796
  • Hebert JR, Rosen A. Nutritional, socioeconomic, and reproductive factors in relation to female breast cancer mortality: findings from a cross-national study. Cancer Detect Prev. 1996;20(3):234-44.

    PubMed 8769718
  • Kodama M, Kodama T, Miura S, Yoshida M. Nutrition and breast cancer risk in Japan. Anticancer Res. 1991 Mar-Apr;11(2):745-54.

    PubMed 2064329
  • Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001 Oct 15;94(2):153-6. doi: 10.1002/ijc.1440. No abstract available.

    PubMed 11668491
  • Reddy BS, Cohen LA, McCoy GD, Hill P, Weisburger JH, Wynder EL. Nutrition and its relationship to cancer. Adv Cancer Res. 1980;32:237-345. doi: 10.1016/s0065-230x(08)60363-2. No abstract available.

    PubMed 6258405
  • Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991 Jun;63(6):963-6. doi: 10.1038/bjc.1991.210.

    PubMed 2069852
  • LeMarchand L, Kolonel LN, Nomura AM. Breast cancer survival among Hawaii Japanese and Caucasian women. Ten-year rates and survival by place of birth. Am J Epidemiol. 1985 Oct;122(4):571-8. doi: 10.1093/oxfordjournals.aje.a114136.

    PubMed 4025300
  • Kanemori M, Prygrocki M. Results of breast conservation therapy from a single-institution community hospital in Hawaii with a predominantly Japanese population. Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):193-7. doi: 10.1016/j.ijrobp.2004.08.054.

    PubMed 15850921
  • Pineda MD, White E, Kristal AR, Taylor V. Asian breast cancer survival in the US: a comparison between Asian immigrants, US-born Asian Americans and Caucasians. Int J Epidemiol. 2001 Oct;30(5):976-82. doi: 10.1093/ije/30.5.976.

    PubMed 11689507
  • Deapen D, Liu L, Perkins C, Bernstein L, Ross RK. Rapidly rising breast cancer incidence rates among Asian-American women. Int J Cancer. 2002 Jun 10;99(5):747-50. doi: 10.1002/ijc.10415.

    PubMed 12115511
  • Fukuda S, Saito H, Nakaji S, Yamada M, Ebine N, Tsushima E, Oka E, Kumeta K, Tsukamoto T, Tokunaga S. Pattern of dietary fiber intake among the Japanese general population. Eur J Clin Nutr. 2007 Jan;61(1):99-103. doi: 10.1038/sj.ejcn.1602505. Epub 2006 Aug 2.

    PubMed 16885928
  • Kotake-Nara E, Asai A, Nagao A. Neoxanthin and fucoxanthin induce apoptosis in PC-3 human prostate cancer cells. Cancer Lett. 2005 Mar 18;220(1):75-84. doi: 10.1016/j.canlet.2004.07.048.

    PubMed 15737690
  • Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem Pharmacol. 2003 Jan 15;65(2):173-9. doi: 10.1016/s0006-2952(02)01478-8.

    PubMed 12504793

Questions about this trial

What is this clinical trial studying?

A study testing Seaweed in people with Seaweed Associated Changes in Healthy Subjects, run by University of South Carolina at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 May 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Urinary urokinase receptor concentration (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01663792, which also lists 31 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in